Any changes to GLP-1 dosing, including maintenance or micro-dosing, should be done under medical supervision to ensure safety, effectiveness, and personalized care.
Dosing every 23 weeks is appropriate only during maintenance phases after initial weight loss has plateaued
Semaglutide's market dominance reflects its superior clinical profile, particularly its once-weekly dosing convenience, dual diabetes and weight management approvals, and groundbreaking cardiovascular outcomes data from the SELECT trial demonstrating a 20% MACE risk reduction
Our heritage | Novo Nordisk | Driving change
Ikoma N, You YN, Bednarski BK, Rodriguez-Bigas MA, Eng C, Das P, Kopetz S , Messick C, Skibber JM, Chang GJ
GLP-1 Insight 22 Alcoholic beverages show a drop in demand, which might mean people are more careful about drinking